aducanumab

Ligand id: 8325

Name: aducanumab

References
1. Biogen. 
Q3 2019 Financial Results and Business Update.
Accessed on 03/12/2019. Modified on 03/12/2019. investors.biogen.com, http://investors.biogen.com/static-files/40565136-b61f-4473-9e58-9be769bbac6c
2. Bussiere T, Weinreb PH, Engber T, Rhodes K, Arndt J, Qian F, Dunstan RW, Patel S. (2014)
A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES.
Patent number: WO2014089500. Assignee: Biogen Idec International Neuroscience Gmbh. Priority date: 07/12/2012. Publication date: 12/06/2014.
3. Howard R, Liu KY. (2020)
Questions EMERGE as Biogen claims aducanumab turnaround.
Nat Rev Neurol, 16 (2): 63-64. [PMID:31784690]
4. Schneider L. (2019)
A resurrection of aducanumab for Alzheimer's disease.
The Lancet Neurology, In Press, Corrected Proof. DOI: 10.1016/S1474-4422(19)30480-6
5. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y et al.. (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Nature, 537 (7618): 50-6. [PMID:27582220]